Palisade Bio, Inc.
PALI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | -0.01 | 0.02 | 0.01 |
| FCF Yield | -55.30% | -55.69% | -71.45% | -24.80% |
| EV / EBITDA | -0.49 | 0.77 | 1.75 | 0.02 |
| Quality | ||||
| ROIC | -78.85% | -103.57% | -42.22% | -43.29% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 1.24 | 0.65 | 1.05 | 0.71 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -95.54% | 22.12% | 2.02% | 24.00% |
| Safety | ||||
| Net Debt / EBITDA | 1.75 | 1.94 | 3.22 | 2.89 |
| Interest Coverage | -584.40 | -1,421.50 | -2,310.00 | -1,127.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -128,340.00 | -123,660.00 | -84,780.00 | -54,090.00 |